Trials / Unknown
UnknownNCT05153850
Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2
Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2 in Patients With Inflammatory Bowel Disease Under Inmunosuppressor Treatment
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 243 (estimated)
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Prospective observational single-center study in which the impact of anti-TNF biological treatment on the humoral response after complete vaccination against SARS-COV2 in patients with inflammatory bowel disease is analyzed.
Detailed description
Prospective observational single-center study in which the impact of anti-TNF biological treatment on the humoral response after complete vaccination against SARS-COV2 in patients with inflammatory bowel disease is analyzed. The first objective is to compare the seroconversion rate after full vaccination against SARS-COV2 in patients with IBD treated with anti-TNF drugs versus patients treated with Ustekinumab / Vedolizumab and patients without immunosuppressive treatment. The Patients included in the study belong to the health area of the Virgen Macarena University Hospital who meet the following inclusion criteria and none for exclusion.
Conditions
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2022-06-01
- Completion
- 2022-09-01
- First posted
- 2021-12-10
- Last updated
- 2022-01-03
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05153850. Inclusion in this directory is not an endorsement.